a Familial hypercholesterolaemia (FH) is the most common inherited metabolic disease characterized by elevated serum levels of low-density lipoprotein cholesterol (LDL-C) and ischaemic heart disease early in life. Early diagnosis and treatment are essential to prevent premature atherosclerosis in FH patients. The aim of our study was the evaluation of the effects of genetic [class of the LDL receptor (LDLR) gene mutation, apolipoprotein (apo)E, apoA-IV and cholesterol ester transfer protein gene polymorphisms] and environmental factors (age, sex, smoking habit and body mass index) on the lipid-lowering response to statin therapy in patients with molecularly defined FH. Atorvastatin 20 mg/day was prescribed in 49 patients with heterozygous FH. The lipid profile was examined before and after 12 weeks of therapy. Statin therapy resulted in a decrease of 37% and 36% in LDL-C and apoB levels, respectively. The study population was then divided into 2 groups according to the class of the LDLR mutation [patients sharing a class V mutation (the G1775A mutation, n = 21) and patients sharing class II mutations (the G1646A and the C858A mutations, n = 28)]. In both groups, the percentage decrement in LDL-C and apoB levels were correlated with the initial LDL-C and apoB levels, respectively. The class of the LDLR mutation affected the LDL-C and apoB-lowering response of heterozygous FH patients to statin therapy. In detail, heterozygotes sharing a class V mutation of the LDLR showed a higher percentage decrement in LDL-C and apoB levels after atorvastatin administration compared to patients sharing class II mutations (49 ± 9% versus 34 ± 9%, P = 0.001 for LDL-C and 42 ± 16% versus 35 ± 20%, P = 0.001 for apoB). The influence of the classes of the LDLR gene mutations on the change of LDL-C and apoB levels to atorvastatin was still significant in a multivariate analysis. None of the other genetic and environmental factors studied affected the lipid-lowering response to atorvastatin therapy in patients with heterozygous FH in a multivariate analysis. Our data indicate that the class of the LDLR gene mutation affects the LDL-C and apoB-lowering response of heterozygous FH patients to statin therapy. Specifically, patients with a class V mutation exhibit higher percentage decrease in LDL-C and apoB levels after statin therapy compared to patients sharing class II mutations.
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Introduction
Familial hypercholesterolaemia (FH) is the commonest genetic disorder characterized by high serum low-density lipoprotein cholesterol (LDL-C) levels, tendon xanthomata and ischaemic heart disease (IHD) early in life. It is an autosomal codominant genetic disease with a frequency of heterozygotes of 1:500 and of homozygotes of 1:1 000 000 in the general population. It typically results from mutations in the gene coding for the LDL-receptor (LDLR). To date, more than 700 gene mutations have been described worldwide causing FH, some of them showing geographical distribution or being founder mutations (http://www.ucl.ac.uk/fh/ genebook.html) [1] [2] [3] [4] [5] [6] [7] [8] . Familial defective apolipoprotein (apo)B 100 is another monogenic disorder characterized by high LDL-C levels, which results from mutations in the apoB 100 gene, and its clinical syndrome is indistinguishable from FH [9, 10] .
Mutations in the LDLR gene have been classified into five classes [11] . Class I mutations (null alleles) include promoter defects, nonsense mutations (stop codons), gross deletions or defects related to mRNA splicing resulting in the elimination of the LDLR synthesis. The more common class II mutations (transport defective alleles) result in LDLRs that fail to be transported from the endoplasmic reticulum to the Golgi complex. Class I and II mutations are also known as receptor negative mutations. Genes carrying the class III mutations (binding defective alleles) produce LDLRs with defective binding to its ligands, apoB 100 and apoE. The products of the genes with class IV mutations (internalization defective alleles) are receptors that fail to concentrate in coated pits in receptor-mediated endocytosis. Finally, class V mutations (recycling defective alleles) result in LDLRs that bind and internalize LDL normally, but fail to release LDL intracellularly and thus the receptors do not return to the cell surface. Class III-V mutations are also known as receptor defective mutations.
Untreated heterozygous FH has a serious prognosis due to lifelong elevated LDL-C levels. Early diagnosis and treatment of FH patients is mandatory to prevent premature atherosclerosis and IHD [12] . Statin therapy is the first choice in patients with heterozygous FH [12] . Data concerning the effect of the LDLR class mutation on the response to statin therapy in patients with molecularly defined FH are controversial. The majority of previously reported data suggest that patients with heterozygous FH carrying receptor defective mutations showed a more pronounced response to hypolipidemic drugs compared to heterozygotes with receptor negative mutations [11, [13] [14] [15] [16] [17] . However, other studies either failed to show an association between the class of the LDLR gene mutations and the response to hypolipidemic drugs in patients with heterozygous FH or showed a better response in heterozygotes with receptor negative mutations compared to heterozygotes with receptor defective mutations [18] [19] [20] [21] .
Apolipoprotein E gene has been referred to as one of the candidate genes possibly affecting the response to statin therapy in patients with heterozygous FH. Similar to LDLR gene mutations, the data concerning the effect of apoE gene polymorphisms on the response to statin therapy in heterozygous FH are controversial. Most studies did not find an association between apoE gene polymorphisms and the statin lipid-lowering effect in patients with heterozygous FH [15, 16, 22, 23] . By contrast, three studies showed that the presence of the apoE e 4 allele was associated with lower LDL-C decrement after statin therapy and one study showed higher LDL-C decrement after statin therapy in heterozygous FH patients compared to patients with the apoE e 2 and e 3 alleles [20, 21, 24, 25] .
To our knowledge, one previous study has examined the effect of the apoA-IV gene polymorphisms on the LDL-C-lowering response to statin therapy in patients with heterozygous FH [26] . Moreover, the effect of cholesterol ester transfer protein (CETP) gene polymorphisms on the response to statin therapy in heterozygotes for FH has not yet been examined.
The present study reports the effect of genetic (LDLR, apoE, apoA-IV and CETP gene polymorphisms) and environmental factors [age, sex, smoking habit and body mass index (BMI)] on the response to statin therapy in Greek patients with molecularly defined FH.
Materials and methods
The study protocol was designed to examine the effect of genetic and environmental factors on the response to statin therapy in patients with molecularly defined heterozygous FH. The study population consisted of 49 unrelated FH patients in whom the genetic defect of the LDLR gene was previously detected [27] . Twenty-eight patients carried the G1646A and C858A mutations, which are class II mutations, and 21 patients were heterozygotes for the G1775A mutation, which is a class V mutation. Apolipoproteins E and A-IV gene polymorphisms and Taq IB CETP polymorphisms were detected using previously described protocols [28] [29] [30] . None of the participants was receiving hypolipidemic drugs or other drugs affecting lipid metabolism (such as b-blockers, diuretics, contraceptives, etc.). After 3 months of dietary intervention, 20 mg/day of atorvastatin was prescribed in all patients for 12 weeks. In all cases, blood samples were obtained after a 14-h overnight fast for the determination of lipid parameters before and after 12 weeks of drug administration. Concentrations of total cholesterol (TCHOL) and TRG were determined enzymatically on the Olympus AU 580 Clinical Chemistry Analyser (Olympus Diagnostica, Hamburg, Germany). High-density lipoprotein-cholesterol (HDL-C) was determined in the supernatant, after precipitation of the apoB-containing lipoproteins with dextran sulphate-Mg 2 + (Sigma Diagnostics, St Louis, Missouri, USA). LDL cholesterol was calculated using the Friedewald formula [31] provided that plasma TRG levels were lower than 400 mg/dl. Apolipoproteins A1, B, E and the lipoprotein (a) [Lp(a)] were measured with a Behring Nephelometer BN100 using reagents (antibodies and calibrators) from Date Behring Holding Gmbh (Liederbach, Germany). The apoA 1 and apoB assays were calibrated according to the International Federation of Clinical Chemistry standards. All participants provided their informed consent for participation in the study, and the study protocol was approved by the ethical committee of our university hospital.
Statistical analysis was performed with SAS statistical software (SAS Institute, Cary, North Carolina, USA) and data are expressed as mean ± SD, expect for Lp(a) which was expressed as median (min-max). Because serum TRG were not normally distributed, triglyceride data were transformed into natural logarithms. A paired Student's t-test was used to examine changes in lipid parameters before and after the drug administration, expect for Lp(a), where the Wilcoxon's signed-rank test was applied. An unpaired Student's t-test was used to test differences in continuous variables between the two groups of different classes of LDLR gene mutations. Chisquare was used to compare percentages. Pearson's correlation coefficients were determined. The percentage changes of LDL-C, apoB, TRG and apoE among the different groups were tested by analysis of covariance, taking the baseline levels of each lipid parameter, respectively, as covariates. Multiple linear regression analysis was used to estimate the independent contributions of the LDLR class mutations, apoE and apoA-IV gene polymorphisms, CETP polymorphisms, sex, smoking habit and BMI to the LDL-C, apoB, TRG and apoE responses to atorvastatin. All variables (genotypes and environmental factors) were entered together in one model for the above analysis. P < 0.05 was considered statistically significant.
Results
The characteristics of the study population are shown in Table 1 . All genotype frequencies were in HardyWeinberg equilibrium. None of the participants had serum TRG levels higher than 400 mg/dl. The administration of atorvastatin in patients with heterozygous FH resulted in a substantial decrease in TCHOL, LDL-C and apoB levels by 32%, 37% and 35%, respectively. In addition, drug administration was associated with a decrement in TRG levels by 15% and apoE levels by 31%. None of the other serum lipid parameters were affected by atorvastatin administration ( Table 2 ).
As shown in Table 3 , there were no differences in age, BMI, sex, smoking habit, apoE, apoA-IV and CETP Taq IB polymorphisms, as well as in baseline serum lipid parameters, between patients carrying different classes of the LDLR gene mutations [class II (group 1) versus class V mutations (group 2)].
As shown in Figs 1 and 2 , the baseline levels of LDL-C and apoB were positively associated with the percentage decrement in LDL-C and apoB, respectively, in both groups [ Figs 1(a and b) and 2(a and b) ].
The effect of genetic factors studied in our cohort on the percentage decrement in LDL-C and apoB levels taking as covariates the baseline LDL-C and apoB levels, respectively, are shown in Table 4 . Heterozygotes for the class V G1775A mutation showed a higher decrease in LDL-C and apoB levels compared to patients with heterozygous FH sharing the G1646A and C858A mutations that are class II mutations (Table 4 ). In a multiple regression analysis, the baseline LDL-C levels and the class of the LDLR gene mutation were the only parameters that significantly affected the percentage decrement in LDL-C (Table 5) . Similarly, the baseline levels of apoB and the class of the LDLR mutation also affected the percentage decrement in apoB in a multivariate analysis (Table 6 ).
Finally, the TRG and apoE-lowering responses to statin therapy were associated with the baseline levels of TRG and apoE, respectively, in both groups studied (data not shown). However, none of the other genetic or environmental factors affected the percentage decrement of TRG and apoE levels in a multivariate analysis (data not shown). 
Discussion
The present study demonstrates that statin therapy results in a significant decrement in LDL-C and apoB levels, as well as in TRG and apoE levels in patients with heterozygous FH. The percentage decrements of the above parameters were positively associated with the baseline values of each parameter in patients carrying class II mutations as well as in patients with a class V mutation. This finding can be explained by the regression to the mean phenomenon. However, the above associations may also be explained by the fact that patients with higher baseline LDL-C and apoB levels have a greater defect of the LDLR activity and thus may exhibit a higher receptor activity after statin administration compared to patients with less severe defects in receptor activity.
The data concerning the effect of the LDLR gene mutations on the LDL-C and apoB-lowering response to statin therapy in patients with heterozygous FH are controversial [11, [13] [14] [15] [16] [17] [18] [19] [20] [21] . Our cohort suggests that patients with heterozygous FH carrying the G1775A (class V mutation) gene mutation responded better to statin therapy compared to heterozygotes with the G1646A and C858A mutations (class II mutations). As expected, heterozygotes for the G1775A mutation had lower baseline LDL-C and apoB levels compared to heterozygotes for the G1646A and C858A mutations (Table 3 , 254 ± 33 mg/dl versus 297 ± 75 mg/dl, and 182 ± 47 mg/dl versus 200 ± 50 mg/dl, respectively). Despite starting with lower baseline LDL-C and apoB levels, patients with heterozygous FH carrying the G1775A mutation responded better to statin therapy compared to heterozygotes with the G1646A and C858A mutations. These results being in keeping with our previously reported data, which showed that statin therapy is effective in some patients with homozygous FH and especially in patients with class V mutations [32] . In detail, when atorvastatin 80 mg/day was administered in seven homozygous patients for the G1775A, a pronounced decrease by 35% in LDL-C levels was observed. Patients with a class V mutation have receptors with normal apoB binding activity, but fail to recycle to the cell membrane after LDL endocytosis [11] . By contrast, the class II mutations of the LDLR gene are characterized by a failure in the transport of the receptor to the cell membrane [11] . Accordingly, statin therapy in patients with heterozygous FH carrying a class V mutation results in more functional receptors in the cell surface and, subsequently, in a higher decrease in LDL-C levels than in heterozygotes with a class II mutation. Moreover, statins could enhance the LDLR recycling to the cell surface after LDL endocytosis, resulting in higher receptor-mediated decrease in LDL-C in patients with a defect in the LDLR recycling to the cell membrane. To our knowledge, only one previous study has examined the differences in response to statin therapy between heterozygotes carrying a class V mutation and those with a class II mutation [17] . The results of the above study are in accordance with our findings. However, the previous authors did not account for their finding indicating a difference in the classes of the LDLR between the patients. Instead, they concluded that the interaction of the mutant and the normal receptor might explain the varying responses between the two groups.
The majority of the studies concerning the effect of the LDLR mutations on the response to statin therapy in patients with heterozygous FH compared patients with receptor negative and receptor defective mutations [13] [14] [15] [16] [17] [18] [19] [20] [21] . However, these groups of patients are heterogeneous, with each group containing more than one class of mutations. This heterogeneity may account for the discrepancy of the results previously reported in the literature with respect to the effect of the LDLR mutations on the response to statin therapy. Table 4 The effect of the genetic factors studied in our cohort on the percentage decrements in low-density lipoprotein-cholesterol (LDL-C) and apolipoprotein (apo)B levels taking as covariates the baseline LDL-C and apoB levels, respectively, in patients with heterozygous familial hypercholesterolaemia (n = 49) Similarly, the data concerning the effect of the apoE gene polymorphisms on the response to statin therapy in patients with heterozygous FH are controversial. The majority of published data do not show an association between apoE polymorphisms and the response to statin therapy in patients with heterozygous FH [15, 16, 22, 23] . Three previously published studies reported that the presence of the e 4 allele was associated with a lower response to statin therapy compared to the presence of e 2 and e 3 alleles [20, 24, 25] . By contrast, Leitersdorf et al.
[21] reported a higher decrement in LDL-C levels after statin therapy in heterozygotes with the e 4 allele compared to heterozygotes with the other alleles. However, the majority of the above reported studies had a limited number of patients, possibly accounting for the controversy concerning the effect of apoE polymorphism on the response to statin therapy. Despite the limited number of patients with the apoE e 4 (n = 9), our data suggest that the apoE polymorphism is not a major factor affecting the response to statin therapy in Greek patients with molecularly defined heterozygous FH.
Apolipoprotein A-IV and CETP play an important role in the metabolism of HDL and TRG-rich lipoproteins [33, 34] . To our knowledge, the effect of apoA-IV and CETP gene polymorphisms on the TRG and apoElowering response to statin therapy in patients with heterozygous FH has not yet been examined. Our study suggests that the above gene polymorphisms did not affect the response to statin therapy in FH patients.
Finally, in accordance with other previously published studies, environmental factors, such as age, sex and BMI, did not affect the response to study therapy in our patients with heterozygous FH [15, 17] . However, Couture et al. [20] and Leitersdorf et al. [21] reported that BMI and gender could affect the response to statin therapy in patients with heterozygous FH. This controversy may be attributed to the different genetic background of each population studied, the limited number of patients in each study and the impact of the other genetic factors on the response to statin therapy in patients with heterozygous FH.
The main limitation of our study is the relatively small number of participants, due to the fact that FH is a rare disorder. Thus, studies with a large number of patients are required to confirm our results.
In conclusion, our data suggest that the class of the LDLR gene mutation affects the response of heterozygous FH patients to statin therapy. Specifically, patients with class V mutation exhibit higher percentage decrements in LDL-C and apoB levels after statin therapy compared to patients sharing class II mutations. The result of the multivariate analysis. b P < 0.05 was considered to be statistically significant.
